Platelet activation in patients after an acute coronary syndrome: Results from the TIMI-12 trial

Journal of the American College of Cardiology

Volumn 33, Issue 3, 1999, Pages 634-639

  Ault, Kenneth A ^a,e   Cannon, Christopher P ^d   Mitchell, Jane ^a   McCahan, John ^a   Tracy, Russell P ^b   Novotny, William F ^c   Reimann, James D ^c   Braunwald, Eugene ^d  

^a MAINE MEDICAL CENTER   (United States)

^b UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^c GENENTECH INC   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e MMCRI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; PADGEM PROTEIN; SIBRAFIBAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; FEMALE; FIBRINOLYTIC THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANGINA, UNSTABLE; BLOOD PLATELETS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OXIMES; P-SELECTIN; PIPERIDINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 0006870550     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00635-4     Document Type: Article

References (31)

1. Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Hemos 1991;65:467-73.
2. Becker RC, Tracy RP, Bovill EG, Mann KG, Ault KA. The clinical use of flow cytometry for assessing platelet activation in acute coronary syndromes. Coron Artery Dis 1994;5:339-45.
3. Bihour C, Durrieu-Jais C, Besse P, Nurden P, Nurden AT. Flow cytometry reveals activated GPIIb/IIIa complexes on platelets from patients undergoing thrombolytic therapy after acute myocardial infarction. Blood Coagul Fibrin 1995;6:395-410.
4. Cahill MR, Macey MG, Dawson JR, Newland AC. Platelet surface activation antigen expression at baseline and during elective angioplasty in patients with mild to moderate coronary artery disease. Blood Coagul Fibrin 1996;7:165-8.
5. Fitzgerald DJ, Roy L, Catella F, Fitzgerald GA. Platelet activation in unstable coronary disease. New Engl J Med 1986;315:983-90.
6. Kolarov P, Tschoepe D, Nieuwenhuis HK, Gries FA, Strauer B, Schultheiss HP. PTCA: Periprocedural platelet activation Part II of the Duesseldorf PTC A platelet study (DPPS). Eur Heart J 1996;17:1216-222.
7. Michelson AD. Flow cytometry: A clinical test of platelet function. Blood 1996;87:4925-36.
8. Murakami T, Komiyama Y, Masuda M, et al. Flow cytometric analysis of platelet activation markers CD62P and CD63 in patients with coronary artery disease. Eur J Clin Invest 1996;26:996-1003.
9. Nurden AT, Macchi L, Bihour C, Durrieu C, Besse P, Nurden P. Markers of platelet activation in coronary heart disease patients. Eur J of Clin Invest 1994;24:42-5.
10. Patrono C, Renda G. Platelet activation and inhibition in unstable coronary syndromes. J Am Coll Cardiol 1997;80:17E-20E.
11. Trip MD, Cats VM, van Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990;322:1549-54.
12. The EPIC Investigators: Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk angioplasty. N Engl J Med 1994;330:956-61.
13. The RESTORE Investigators. The effects of glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997;96:1445-53.
14. The Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. N Engl J Med 1989;321:129-35.
15. The PRISM-PLUS Investigators. Inhibition of platelet glycoprotein IIb/IIIa with tirofiban in unstable angina and non Q wave myocardial infarction. N Engl J Med 1998;338:1488-97.
16. The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrelin Therapy (PURSUIT) Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: a randomized placebo-controlled clinical trial. N Engl J Med 1998;339:436-43.
17. Ferguson J, Deedwania P, Kereiakas D, et al. Sustained platelet GPIIb/IIIa blockade with oral orofiban: Interim pharacodynamic results of the SOAR study (abstract). J Am Coll Cardiol 1998;31:185A.
18. Cannon C, McCabe C, Borzak S, et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, Sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Circulation 1997;97:340-9.
19. Kereiakes D, Runyon J, Kleiman N, Higby N, Anderson L, Hantsbarger G, McDonald S, Anders R. Differential dose-response to oral xemilofiban after antecedant intravenous abciximab: Administration for complex secondary intervention. Circulation 1996;94:906-10.
20. Ault KA, Rinder HM, Mitchell JG, Rinder CS, Lambrew CT, Hillman RS. Correlated measurement of platelet release and aggregation in whole blood. Cytometry 1989;10:448-55.
21. Ault KA. Flow cytometric measurement of platelet function and reticulated platelets. Ann N Y Acad Sci 1993;677:293-308.
22. Ault KA, Mitchell J. Analysis of platelets by flow cytometry. Methods Cell Biol 1994;42:275-94.
23. Carmody MW, Ault KA, Mitchell JG, Rote NS, Ng AK. Production of monoclonal antibodies specific for platelet activation antigens and their use in evaluating platelet function. Hybridoma 1990;9:631-41.
24. Rinder CS, Bohnert J, Rinder HM, Mitchell J, Ault KA, Hillman RS. Platelet activation and aggregation during cardiopulmonary bypass. Anaesthesiology 1991;75:388-93.
25. Abrams CS, Ellison N, Brudzynski AZ, Shattil SJ. Direct detection of activated platelets and platelet derived microparticles in human blood. Blood 1990;87:492S-36.
26. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation dependent monoclonal antibodies and flow cytometry. Blood 1987;70:307-15.
27. McEver RP, Martin MN. A monoclonal antibody to a membrane glycoprotein binds only to activated platelets. J Biol Chem 1984;259:9799-804.
28. Becker R, Bovill E, Corrao J, Ball S, Ault K, Mann K, Tracy R. Dynamic nature of thrombin generation, fibrin formation, and platelet activation in unstable angina and non-Q-wave myocardial infarction. J Thromb Thrombol 1995;2:57-64.
29. Blann AD, Lip GY. Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis 1997;128:135-8.
30. Ikeda H, Nakayama H, Oda T, Kuwano K, Muraishi A, Sugi K, Koga Y, Toshima H. Soluble form of P-selectin in patients with acute myocardial infarction. Coron Artery Dis 1994;5:515-8.
31. Ikeda H, Takajo Y, Ichiki K, et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation 1995;92:1693-6.